Premium
Clinical implication of human leukocyte antigen ( HLA )‐ F expression in breast cancer
Author(s) -
Harada Aya,
Ishigami Sumiya,
Kijima Yuko,
Nakajo Akihiro,
Arigami Takaaki,
Kurahara Hiroshi,
Kita Yoshiaki,
Yoshinaka Heiji,
Natsugoe Shoji
Publication year - 2015
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12343
Subject(s) - hla g , human leukocyte antigen , breast cancer , stromal cell , antigen , cancer , immunohistochemistry , medicine , stage (stratigraphy) , immunology , pathology , biology , paleontology
Human leukocyte antigen ( HLA )‐ F is one of the non‐classical HLA class I molecules that protects the fetus in pregnancy. HLA ‐ F expression was immunohistochemically examined and the association between clinical parameters and HLA ‐ F expression was analyzed. Cancerous HLA ‐ F and stromal HLA ‐ F ‐positive infiltrating cells were detected in 91 (40.0%) and 186 (81.6%) cases, respectively. HLA ‐ F positivity in cancer cells was significantly associated with tumor size ( P < 0.05). There was a weak correlation between HLA ‐ F positivity of cancer cells and HLA ‐ F positive infiltrative cells ( P < 0.01, r = 0.11). HLA ‐ F positivity did not affect patients' survival in 209 breast cancer. However, confined to stage II breast cancer, the HLA ‐ F positive group showed significantly poorer outcomes than the HLA ‐ F negative group ( P < 0.05). The present study provides the first evidence that HLA ‐ F positivity in breast carcinoma affects clinicopathological factors and could be selected as a prognostic marker for limited clinical stage.